Navigation Links
Cephalon Conference Call Invitation
Date:5/5/2008

Tuesday, May 6, 2008, 5:30 p.m. U.S. EDT

FRAZER, Pa., May 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced plans to host an investor conference call at 5:30 p.m. EDT on May 6, 2008 to discuss the U.S. Food and Drug Administration advisory committee panel meeting held that day. The advisory committee panel is considering the company's supplemental New Drug Application for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain.

May 6, 2008 Schedule

5:20 p.m. EDT To participate in the conference call, dial 913-312-0407

and refer to Conference Code Number 2046179

5:30 p.m. EDT Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information" then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EDT, May 20, 2008. To listen to the audio replay, dial 719- 457-0820 and use the Conference Code Number 2046179.

Additional information presented on the conference call may be made available on the Investor Information page of the company's website.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cephalon Reports Strong First Quarter Earnings
2. Cephalon Appoints Gerald J. Pappert as General Counsel
3. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
4. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
5. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
7. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
8. United American Healthcare Corporation to Host Fiscal 2008 Third Quarter Results Conference Call May 13th
9. Digirad Corporation to Present at Bank of America 2008 Health Care Conference
10. Zimmer Holdings to Present at Deutsche Bank 33rd Annual Health Care Conference
11. American Pacific to Release Financial Results and Hold Fiscal 2008 Second Quarter Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a competitive ... at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s ... hearing healthcare providers to help them stay ahead in the industry. At the event, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original ... discounted crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget ... a fidget toy to the market that was made of superior quality and wouldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology: